Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Global Advanced Drug Delivery Market to Generate a Revenue of $94,352.5 Million by 2028, Growing at a CAGR of 10.0% from 2021-2028 [175-pages] | Declared by Research Dive

This image opens in the lightbox

News provided by

Research Dive

06 Jul, 2022, 13:10 GMT

Share this article

Share toX

Share this article

Share toX

The global advanced drug delivery market is expected to grow rapidly by 2028, owing to the growing cases of cancer. The hospital sub-segment is expected to be most profitable. The North America region is expected to dominate the global market.

NEW YORK, July 6, 2022 /PRNewswire/ -- Research Dive has added a new report to its offering titled, 'Advanced Drug Delivery Market by Drug Delivery System (Nanocarriers, Hydrogel, Transdermal, and Microneedle Patch), End-user (Hospitals, Specialty Clinics, and Others), and Regional Analysis (North America, Europe, Asia-Pacific, and LAMEA): Global Opportunity Analysis and Industry Forecast, 2021–2028'.

According to the report published by Research Dive, the global advanced drug delivery market is expected to generate a revenue of $94,352.5 million by 2028, growing exponentially at a CAGR of 10.0% during the forecast period 2021-2028.

Request an Exclusive PDF Sample of the Advanced Drug Delivery Market

Dynamics of the Advanced Drug Delivery Market

Availability of improved healthcare infrastructure and advanced diagnosis facilities is expected to drive the growth of the advanced drug delivery market during the forecast period. In addition, wide application of nanoparticle-based drug delivery systems in the treatment of cancer is expected to bolster the growth of the market during the forecast period. Furthermore, significant surge in R&D activities to create advanced drug delivery systems is expected to create tremendous opportunities for the growth of the advanced drug development market during the forecast period. However, poor bioavailability of nanoparticle-based drug discovery is expected to impede the growth of the advanced drug delivery market during the forecast period.

COVID-19 Impact on the Advanced Drug Delivery Market

The outbreak of COVID-19 has had a negative impact on the growth of the global advanced drug delivery market, owing to the prevalence of stringent restrictions imposed by the government during the pandemic. The fear of spreading coronavirus adversely impacted most of the phases of the drug development process, and hence most of the research, pharmaceuticals, and biotechnology institutes halted their production and rigorous R&D activities. There was also a huge shortage of life-saving medicines in most of the affected countries across the globe. Thus, coronavirus has had a negative impact on the growth of the market during the forecast period.

Grow your business in Post COVID-19 Pandemic of Advanced Drug Delivery Market. Get in touch with our Expert Analyst

Segments of the Advanced Drug Delivery Market

The report has divided the advanced drug delivery market into various segments based on drug delivery system, end-user, and region.

  • By drug delivery system, the nanocarriers sub-segment is expected to be most profitable, and generate a revenue of $69,389.3 million during the forecast period. Significant surge in R&D investments and growing importance of nanocarriers in accurately delivering drugs at the target site is expected to stimulate the growth of the advanced drug delivery market sub-segment during the forecast period.
  • By end-user, the hospital sub-segment is expected to be most lucrative, and generate a revenue of $44,710.0 million during the forecast period. Presence of advanced diagnosis instruments and growing number of patients attending hospitals for treatments are expected to surge the growth of the advanced drug delivery market sub-segment during the forecast period.
  • By region, the North America region is expected to dominate the global market, and generate a revenue of $39,722.4 million during the forecast period. Rising prevalence of cancer, obesity, and heart diseases among people living in this region is expected to drive the growth of the market during the forecast period. In addition, immense presence of skilled doctors and medical practitioners in this region is further expected to accelerate the growth of the regional advanced drug delivery market during the forecast period.

Personalize the Advanced Drug Delivery Market Research Report. & Avail Amazing Discount

Key Players of the Market

The major players of the market include

  1. Bausch Health Companies Inc.
  2. Novo Nordisk A/S
  3. Altaris
  4. Micropoint Technologies.
  5. Takeda Pharmaceutical Company Limited
  6. Ocular Therapeutix, Inc.
  7. 3M
  8. Raphas Co., Ltd.
  9. GALDERMA
  10. NanoPass

These players are working on developing strategies such as product development, merger and acquisition, partnerships and collaborations to sustain the market growth.

For instance, in January 2022, Merck KGaA, a Germany-based dominant science and technology company that operates across life science, healthcare, and electronics, acquired Exelead, a dynamic innovative platform that is engaged in developing and producing liposomal and LNP drug product formulations, in order help Merck capture prominent potential of the fast-growing market for mRNA therapies. Inquire here before buying the full report

The report also summarizes many important aspects including financial performance of the key players, SWOT analysis, product portfolio, and latest strategic developments.

More about Advanced Drug Delivery Market:

  • A Concise Outlook on Advanced Drug Delivery Systems
  • Acquisitions like That of Dicerna Pharmaceuticals by Novo Nordisk to Propel the Growth of Advanced Drug Delivery Market

Some Trending Article Links:

  • According to a new study conducted by Research Dive, the global antiviral therapies market size will reacha bout $66,016.5 million till 2027
  • The global fatty bases for suppositories market forecast is predicted tobe $6,565.1 million by 2027, increasing from $5,246.5 million in 2019 at a healthy CAGR of 2.7%
  • The private nursing service market size was $834.2 billion in 2018 and is predicted to grow by generating a revenue of $1,299.8 billion by 2026

About Research Dive

Research Dive is a market research firm based in Pune, India. Maintaining the integrity and authenticity of the services, the firm provides the services that are solely based on its exclusive data model, compelled by the 360-degree research methodology, which guarantees comprehensive and accurate analysis. With an unprecedented access to several paid data resources, team of expert researchers, and strict work ethic, the firm offers insights that are extremely precise and reliable. Scrutinizing relevant news releases, government publications, decades of trade data, and technical & white papers, Research dive deliver the required services to its clients well within the required timeframe. Its expertise is focused on examining niche markets, targeting its major driving factors, and spotting threatening hindrances. Complementarily, it also has a seamless collaboration with the major industry aficionado that further offers its research an edge.

Contact:
Mr. Abhishek Paliwal
Research Dive
30 Wall St. 8th Floor, New York NY 10005
(P) +91-(788)-802-9103 (India)
+1-(917)-444-1262 (US)
Toll Free: 1-888-961-4454
E-mail: support@researchdive.com 
Website: 
https://www.researchdive.com
Blog: 
https://www.researchdive.com/blog/
LinkedIn: 
https://www.linkedin.com/company/research-dive/
Twitter: 
https://twitter.com/ResearchDive
Facebook: 
https://www.facebook.com/Research-Dive-1385542314927521 

Logo: https://mma.prnewswire.com/media/997523/Research_Dive_Logo.jpg

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.